Cargando…
A rare case of acquired factor V inhibitor, during treatment with dabigatran for chronic atrial fibrillation, successfully treated with bypassing agents
Acquired factor V inhibitor represents a rare condition, described only in case reports. The use of activated bypassing agents in bleeding control could be of aid and improve the survival in symptomatic patients with acquired factor V inhibitor.
Autores principales: | Giuffrida, Gaetano, Markovic, Uros, Nicolosi, Daniela, Calafiore, Valeria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869404/ https://www.ncbi.nlm.nih.gov/pubmed/33598214 http://dx.doi.org/10.1002/ccr3.3586 |
Ejemplares similares
-
Acquired hemophilia in a 7‐year‐old girl successfully treated with recombinant FVIIA and steroids: A case report
por: Giuffrida, Gaetano, et al.
Publicado: (2020) -
Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011) -
Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
por: Giuffrida, Gaetano, et al.
Publicado: (2023) -
Immune Thrombocytopenic Purpura Cases Following COVID-19 Vaccination
por: Condorelli, Annalisa, et al.
Publicado: (2021) -
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012)